202 related articles for article (PubMed ID: 11289162)
21. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.
Kobatake T; Yano M; Toyooka S; Tsukuda K; Dote H; Kikuchi T; Toyota M; Ouchida M; Aoe M; Date H; Pass HI; Doihara H; Shimizu N
Oncol Rep; 2004 Nov; 12(5):1087-92. PubMed ID: 15492797
[TBL] [Abstract][Full Text] [Related]
22. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
23. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
24. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
[TBL] [Abstract][Full Text] [Related]
25. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
26. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
[TBL] [Abstract][Full Text] [Related]
27. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
28. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
29. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
30. MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland.
Billard LM; Magdinier F; Lenoir GM; Frappart L; Dante R
Oncogene; 2002 Apr; 21(17):2704-12. PubMed ID: 11965543
[TBL] [Abstract][Full Text] [Related]
31. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
[TBL] [Abstract][Full Text] [Related]
32. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
[TBL] [Abstract][Full Text] [Related]
33. Promoter hypermethylation of cyclooxygenase-2 in gastric carcinoma.
Yu J; Leung WK; Lee TL; Tse PC; To KF; Sung JJ
Int J Oncol; 2003 May; 22(5):1025-31. PubMed ID: 12684668
[TBL] [Abstract][Full Text] [Related]
34. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
35. IGSF4 promoter methylation and expression silencing in human cervical cancer.
Li J; Zhang Z; Bidder M; Funk MC; Nguyen L; Goodfellow PJ; Rader JS
Gynecol Oncol; 2005 Jan; 96(1):150-8. PubMed ID: 15589594
[TBL] [Abstract][Full Text] [Related]
36. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma.
Zhu XL; Hartwick W; Rohan T; Kandel R
Mod Pathol; 1998 Nov; 11(11):1082-8. PubMed ID: 9831206
[TBL] [Abstract][Full Text] [Related]
37. [Methylation status and protein expression of adenomatous polyposis coli (APC) gene in breast cancer].
Liu Z; Yang L; Cui DX; Liu BL; Zhang XB; Ma WF; Zhang Q
Ai Zheng; 2007 Jun; 26(6):586-90. PubMed ID: 17562262
[TBL] [Abstract][Full Text] [Related]
38. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast.
Lee A; Kim Y; Han K; Kang CS; Jeon HM; Shim SI
Arch Pathol Lab Med; 2004 Nov; 128(11):1251-6. PubMed ID: 15508191
[TBL] [Abstract][Full Text] [Related]
39. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation.
Loeb DM; Evron E; Patel CB; Sharma PM; Niranjan B; Buluwela L; Weitzman SA; Korz D; Sukumar S
Cancer Res; 2001 Feb; 61(3):921-5. PubMed ID: 11221883
[TBL] [Abstract][Full Text] [Related]
40. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.
Lewis CM; Cler LR; Bu DW; Zöchbauer-Müller S; Milchgrub S; Naftalis EZ; Leitch AM; Minna JD; Euhus DM
Clin Cancer Res; 2005 Jan; 11(1):166-72. PubMed ID: 15671542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]